Medicare and Medicaid Reforms That Can Help Curb Costs

Increased use of comparative effectiveness research in funding decisions for Medicare and Medicaid programs will ensure technologic advancements demonstrate cost containment strategies and improved quality of health care services when new medical innovation is proposed for use in the United States’ health care system, thereby reducing overall health care expenditures.

Public and private health care expenditures in the United States have grown at unprecedented rates over the past four decades, rising faster than average income. The development and rapid spread of medical technology serve as the key drivers of health care spending, with new medical technology accounting for a large percentage of health care spending growth. Medical technology refers to the equipment and processes used to deliver medical care and health care services. This includes new medical and surgical procedures, pharmaceutical drugs, medical devices and support systems, and medical technology. Greater availability of new medical technology facilitates higher spending on services due to increased per capita usage.

Analysis

Innovation has resulted in major advances in clinical abilities, the development of new procedures and treatments (including treatments for previously untreated terminal conditions), and improvements in the scope of medicine covered through the health care system. Through effective health technology assessments, it becomes possible to explore strategies to control rising costs without stifling technological innovation. Health technology assessment, the process by which health care systems conduct cost-benefit analysis for new technology, is particularly important in determining the spread of innovation. Assessments should be carried out in conjunction with comparative effectiveness research (CER), which is “designed to inform health care decisions by providing evidence on the effectiveness, benefits and harms of different treatment options.”5 The $1 billion in funding for CER through the American Recovery and Reinvestment Act, as well as the support for CER through the 2010 Affordable Care Act, present critical steps toward establishing the end goal of patient-centered outcomes research. While this research will determine the clinical effectiveness of medical treatments, new technology must also be assessed for cost-effectiveness and cost-benefits analysis when compared with existing technology. 

Without proper evaluation of new technology, there is a direct result of increased health care costs because of the United States’ primarily third-party payer system. New medical technologies are developed with the ability to spread based on a health care provider’s willingness to pay for such services. In this model, third-party payers determine what new technology is deemed effective and efficient based on individual standards.

Next Steps

The United States government should expand the mandate of the Technology Assessment Program through the Agency for Healthcare Research and Quality. This program is primarily responsible for assessing the cost-effectiveness and benefits of new technology as compared to existing technologies. In addition, it should introduce policy that requires manufacturers to demonstrate the effectiveness of technological innovation on quality of care as compared to existing technology rather than a placebo.

How much do you trust the information in this article?

Adam Jutha

B.S. Public Health - Health Policy and Management from the University of North Carolina at Chapel Hill. Former member of the Roosevelt Institute | Campus Network. Interests lie in health care policy, international development, and politics.

MORE FROM

Sam Brownback: 3 things to know about Trump’s nominee for ambassador-at-large for religious freedom

Brownback was a key sponsor of the International Religious Freedom Act of 1998, which created the job he's now nominated for.

Hundreds rally in Times Square to protest Donald Trump’s transgender military ban

“I’m out here to support my trans brothers and sisters who have been serving our military for years and years and years."

Several Republicans are strongly denouncing Trump’s military transgender ban

“Anybody who wants to serve in the military should serve in the military. I don’t agree with the president.”

Worried Trump might pardon himself? Blame Alexander Hamilton.

Hamilton might not have been "thinkin' past tomorrow" when he pushed for broad executive privileges.

Harry Truman desegregated the military 69 years ago. Today, Trump banned transgender troops.

Truman wanted to end discrimination in the military "as rapidly as possible."

Here is a timeline of Donald Trump’s relationship with Jeff Sessions

Trump continued his Twitter attacks on Sessions Wednesday — reportedly while the embattled attorney general was in the White House.

Sam Brownback: 3 things to know about Trump’s nominee for ambassador-at-large for religious freedom

Brownback was a key sponsor of the International Religious Freedom Act of 1998, which created the job he's now nominated for.

Hundreds rally in Times Square to protest Donald Trump’s transgender military ban

“I’m out here to support my trans brothers and sisters who have been serving our military for years and years and years."

Several Republicans are strongly denouncing Trump’s military transgender ban

“Anybody who wants to serve in the military should serve in the military. I don’t agree with the president.”

Worried Trump might pardon himself? Blame Alexander Hamilton.

Hamilton might not have been "thinkin' past tomorrow" when he pushed for broad executive privileges.

Harry Truman desegregated the military 69 years ago. Today, Trump banned transgender troops.

Truman wanted to end discrimination in the military "as rapidly as possible."

Here is a timeline of Donald Trump’s relationship with Jeff Sessions

Trump continued his Twitter attacks on Sessions Wednesday — reportedly while the embattled attorney general was in the White House.